Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Mathis

Sports Medicine La Grande, OR Medical Doctor

NPI 1225033350 CMS profile 327808

710 Sunset Dr Ste F, La Grande, OR 97850

Open in the dashboard

General payments

$7,779

164 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Mathis of La Grande, OR is reported in the CMS Open Payments database as having received $7,779 across 164 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,081 7
2024 General $36 1
2023 General $1,536 35
2022 General $3,028 67
2021 General $1,633 38
2020 General $352 6
2019 General $113 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Mathis
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to James Mathis were reported at $1,081. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year James Mathis Sports Medicine median Middle half National median
2019 $113 $1,176 $199–$4,249 $163
2020 $352 $708 $96–$2,890 $114
2021 $1,633 $1,213 $152–$3,994 $132
2022 $3,028 $1,230 $159–$3,998 $149
2023 $1,536 $584 $146–$2,836 $160
2024 $36 $628 $163–$3,168 $164
2025 $1,081 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. MicroPort Orthopedics Inc $3,120 33 payments
  2. Medinc of Texas $1,257 3 payments
  3. Zimmer Biomet Holdings, Inc. $1,075 6 payments
  4. Stryker Corporation $778 59 payments
  5. Exactech, Inc. $639 4 payments
  6. Medacta USA, Inc. $407 47 payments
  7. Anika Therapeutics, Inc. $142 1 payment
  8. Conformis, Inc. $135 1 payment
  9. Alafair Biosciences,Inc. $40 1 payment
  10. Innovation Technologies Inc $36 1 payment
  11. Other $150 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,604 148 payments
  2. Travel and Lodging $2,975 15 payments
  3. Education $1,200 1 payment
Products named General payments · program years 2019–2025
  1. MPO Medial Pivot Knee $1,843 19 payments
  2. MPO Hip System $1,270 13 payments
  3. Equinoxe $531 3 payments
  4. PROFYLE $477 40 payments
  5. Oxford $338 3 payments
  6. GMK SPHERE $208 26 payments
  7. OMEGA $178 12 payments
  8. RevoMotion $142 1 payment
  9. iTotal Identity PS $135 1 payment
  10. OPTETRAK $108 1 payment
  11. Other $657 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

627

Median for Orthopedic Surgery: 203

Drug cost

$4,624

Median for Orthopedic Surgery: $1,433

Branded share of claims

18.7%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 60 $1,692
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 94 $719
Cefadroxil Generic 80 $347
Gabapentin Generic 88 $303
Oxycodone Hcl Generic 51 $240
Cyclobenzaprine Hcl Generic 46 $230
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 23 $228
Methylprednisolone Generic 30 $211
Tizanidine Hcl Generic 22 $197
Tramadol Hcl Generic 56 $144

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$109,742

Of which drugs: $1,388

Medicare patients

251

Average age 76

Services billed

1,007

144 women, 107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 35%
Diabetes 30%
Chronic kidney disease 25%
Atrial fibrillation 23%
Heart failure 22%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 35 242 $169

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

164 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record